Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.2500 +0.0076 (+3.14%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Adaptimmune Therapeutics
Via Benzinga
Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in... 
Via Newsfile
Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
An Overview of Adaptimmune Therapeutics's Earnings
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast
Via Benzinga
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Tuesday's after hours session: top gainers and losers
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
What Analysts Are Saying About Adaptimmune Therapeutics Stock
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Top movers in Thursday's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results
Via Benzinga
Topics Stocks
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and... 
Via Newsfile
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working... 
Via Newsfile
Earnings Scheduled For March 20, 2025
Via Benzinga
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other... 
Via Newsfile
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,... 
Via Newsfile
Topics Initial Public Offering
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company... 
Via Newsfile
Adaptimmune Reports Q3 2024 Financial and Business Updates
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed... 
Via Newsfile
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses... 
Via Newsfile
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working... 
Via Newsfile
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.